Trials / Completed
CompletedNCT02743637
A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors
A Phase 1 Dose Escalation Study of SDX-7320 to Assess the Safety and Tolerability in Patients With Advanced Refractory or Late-Stage Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- SynDevRx, Inc. · Industry
- Sex
- All
- Age
- 21 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1 dose escalation to assess the safety, tolerability and maximum tolerated dose of subcutaneous administered SDX-7320 in patients with advanced refractory or late-stage solid tumors.
Detailed description
This is a Phase 1 dose escalation study to assess the safety and tolerability of subcutaneously administered SDX-7320 in patients with advanced refractory or late-stage solid tumors. Once the MTD has been determined up to 12 patients will be treated at this dose level, to further characterize treatment emergent adverse events (TEAEs).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SDX-7320 | SDX-7320 is a synthetic copolymer-drug conjugate of a novel MetAP2 inhibitor. |
Timeline
- Start date
- 2016-02-01
- Primary completion
- 2019-12-16
- Completion
- 2019-12-16
- First posted
- 2016-04-19
- Last updated
- 2020-01-27
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02743637. Inclusion in this directory is not an endorsement.